Skip to main content
SpringerLink
Log in
Book cover

Encyclopedia of AIDS pp 1–5Cite as

Maturation Inhibitor

  • Living reference work entry
  • First Online:

  • 290 Accesses

Definition

Maturation inhibitors are a class of HIV antiretroviral agents currently in development. They act at the viral maturation step, which involves cleavage of the structural protein “Gag,” resulting in the development of an infective viral particle. These agents aim to stop viral maturation by inhibiting Gag cleavage. While not currently in clinical use, they represent a promising new therapeutic class for HIV infection.

Introduction

Combination antiretroviral agents with distinct mechanisms have become the mainstay of therapy for HIV infection. A variety of drug classes are available for use, as discussed elsewhere in this text, targeting viral enzymes including reverse transcriptase (RT), protease (PR), and integrase (IN). All currently recommended antiretroviral regimens use a combination of the above classes to provide therapeutic effect (Panel on Antiretroviral Guidelines for Adults and Adolescents 2014; Gunthard et al. 2014). The rationale for a combination approach to...

This is a preview of subscription content, log in via an institution.

References

  • Adamson CS, Freed EO. Human immunodeficiency virus type 1 assembly, release, and maturation. Adv Pharmacol. 2007;55:347–87.

    Article  CAS  PubMed  Google Scholar 

  • Adamson CS, Ablan SD, Boeras I, et al. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol. 2006;80(22):10957–71.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Adamson CS, Sakalian M, Salzwedel K, Freed EO. Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat. Retrovirology. 2010;7:36.

    Article  PubMed Central  PubMed  Google Scholar 

  • Baichwal V, Austin H, Brown B, et al. Anti-viral characteristics in vitro of a novel maturation inhibitor, MPC-9055. In: Conference on retroviruses and opportunistic infections, Montreal; 2009.

    Google Scholar 

  • Checkley MA, Luttge BG, Soheilian F, Nagashima K, Freed EO. The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation. Virology. 2010;400(1):137–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Erickson-Viitanen S, Manfredi J, Viitanen P, et al. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res Hum Retroviruses. 1989;5(6):577–91.

    Article  CAS  PubMed  Google Scholar 

  • Ganser-Pornillos BK, Yeager M, Sundquist WI. The structural biology of HIV assembly. Curr Opin Struct Biol. 2008;18(2):203–17.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312(4):410–25.

    Article  PubMed  Google Scholar 

  • Haqqani AA, Tilton JC. Entry inhibitors and their use in the treatment of HIV-1 infection. Antiviral Res. 2013;98(2):158–70.

    Article  CAS  PubMed  Google Scholar 

  • Hwang C, Sevinsky H, Ravindran P, et al. Antiviral activity/safety of a second-generation HIV-1 maturation inhibitor. In: Conference on retroviruses and opportunistic infections, Seattle; 2015.

    Google Scholar 

  • Kanamoto T, Kashiwada Y, Kanbara K, et al. Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother. 2001;45(4):1225–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Keller PW, Adamson CS, Heymann JB, Freed EO, Steven AC. HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice. J Virol. 2011;85(4):1420–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Krausslich HG, Schneider H, Zybarth G, Carter CA, Wimmer E. Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli. J Virol. 1988;62(11):4393–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Li F, Goila-Gaur R, Salzwedel K, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A. 2003;100(23):13555–60.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Li F, Zoumplis D, Matallana C, et al. Determinants of activity of the HIV-1 maturation inhibitor PA-457. Virology. 2006;356(1–2):217–24.

    Article  CAS  PubMed  Google Scholar 

  • Llibre JM, Rivero A, Rojas JF, et al. Safety, efficacy and indications of prescription of maraviroc in clinical practice: factors associated with clinical outcomes. Antiviral Res. 2015;120:79–84.

    Article  CAS  PubMed  Google Scholar 

  • Lu W, Salzwedel K, Wang D, et al. A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat. Antimicrob Agents Chemother. 2011;55(7):3324–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Margot NA, Gibbs CS, Miller MD. Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat. Antimicrob Agents Chemother. 2010;54(6):2345–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Martin DE, Blum R, Wilton J, et al. Safety and pharmacokinetics of bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother. 2007a;51(9):3063–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Martin DE, Blum R, Doto J, Galbraith H, Ballow C. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. Clin Pharmacokinet. 2007b;46(7):589–98.

    Article  CAS  PubMed  Google Scholar 

  • Martin DE, Galbraith H, Schettler J, Ellis C, Doto J. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study. Clin Ther. 2008;30(10):1794–805.

    Article  CAS  PubMed  Google Scholar 

  • McCallister S, Lalezari J, Richmond G, et al. HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457). Antivir Ther. 2008;13:A10.

    Google Scholar 

  • Muller B, Anders M, Akiyama H, et al. HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J Biol Chem. 2009;284(43):29692–703.

    Article  PubMed Central  PubMed  Google Scholar 

  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, §What to Start. 2014.

    Google Scholar 

  • Seclen E, Gonzalez Mdel M, Corral A, de Mendoza C, Soriano V, Poveda E. High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to bevirimat, an HIV-1 maturation inhibitor. AIDS. 2010;24(3):467–9.

    Article  CAS  PubMed  Google Scholar 

  • Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet. 2006;368(9534):489–504.

    Article  PubMed Central  PubMed  Google Scholar 

  • Smith PF, Ogundele A, Forrest A, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′,3′-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007;51(10):3574–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Sundquist WI, Krausslich HG. HIV-1 assembly, budding, and maturation. Cold Spring Harb Perspect Med. 2012;2(7):a006924.

    Article  PubMed Central  PubMed  Google Scholar 

  • Swanstrom R, Wills JW. Synthesis, assembly, and processing of viral proteins. In: Coffin JM, Hughes SH, Varmus HE, editors. Retroviruses. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1997.

    Google Scholar 

  • Temesgen Z, Cainelli F, Poeschla EM, Vlahakis SA, Vento S. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. Lancet Infect Dis. 2006;6(8):496–507.

    Article  CAS  PubMed  Google Scholar 

  • Van Baelen K, Salzwedel K, Rondelez E, et al. Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob Agents Chemother. 2009;53(5):2185–8.

    Article  PubMed Central  PubMed  Google Scholar 

  • Verheyen J, Verhofstede C, Knops E, et al. High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. AIDS. 2010;24(5):669–73.

    Article  CAS  PubMed  Google Scholar 

  • Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Krausslich HG. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol. 1998;72(4):2846–54.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Yebra G, Holguin A. The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants. Antivir Ther. 2008;13(8):1083–5.

    PubMed  Google Scholar 

  • Zhou J, Yuan X, Dismuke D, et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol. 2003;78(2):922–9.

    Article  Google Scholar 

  • Zhou J, Chen CH, Aiken C. Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3′,3′-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. J Virol. 2006;80(24):12095–101.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, 125, 10065, New York, NY, USA

    Shashi Kapadia & Marshall J. Glesby

Authors
  1. Shashi Kapadia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marshall J. Glesby
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shashi Kapadia .

Editor information

Editors and Affiliations

  1. Dept. Cell & Molecular Biology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA

    Thomas J. Hope

  2. Office of Graduate and Postdoctoral Studies, University of Miami, Miller School of Medicine, Miami, Florida, USA

    Mario Stevenson

  3. University of California, San Diego Dept. Pathology, La Jolla, California, USA

    Douglas Richman

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this entry

Cite this entry

Kapadia, S., Glesby, M.J. (2015). Maturation Inhibitor. In: Hope, T., Stevenson, M., Richman, D. (eds) Encyclopedia of AIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9610-6_452-1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-9610-6_452-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Online ISBN: 978-1-4614-9610-6

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation